Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Risk Reduction in the Diabetic Patient

  • Chapter
  • First Online:
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Part of the book series: Current Clinical Practice ((CCP))

Abstract

Diabetic patients are at high risk for cardiovascular mortality, the greatest cause being atherosclerotic vascular disease and its subsequent sequelae. Diabetic patients have greater risk of permanent brain damage with carotid emboli, threefold greater mortality from stroke, poor prognosis for survival, and a two to fourfold greater risk of cardiovascular disease. In the Framingham Heart study, men with type-2 diabetes are twice as likely to develop heart failure compared to non-diabetics and women are five times more likely. The management and control of cardiovascular disease may be the most challenging and elusive task since cardiovascular damage may already be present even before the disease is diagnosed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Spanheimer RG. Reducing cardiovascular risk in diabetes. Which factors to modify first? Postgrad Med 2001;109:26–36.

    PubMed  CAS  Google Scholar 

  2. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA diabetes trial. Diabetes Care 2001;24:942–945.

    Article  PubMed  CAS  Google Scholar 

  3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neal HA. Ten year follow up of intensive glucose control in type-2 diabetes. N Engl J Med 2008;359(15):1577–1589.

    Article  PubMed  CAS  Google Scholar 

  4. Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type-2 diabetes. The ADVANCE Trial. N Engl J Med 2008;358:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  5. Gerstein HC, Riddle MC, Kendall DM. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:34i–43i.

    Article  PubMed  Google Scholar 

  6. Magee MF, Isley WL. Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2) trial. AM J Cardiol 2006;97:20G–30G.

    Article  PubMed  Google Scholar 

  7. Weintraub W, Spertus J, Kolm P, Maron D, Zhang Z. Effect of PCI on quality of life in patients with stable coronary artery disease. N Engl J Med 2008;359:677–687.

    Article  PubMed  CAS  Google Scholar 

  8. Greenfield S, Billimek J, Pelligrini F, Franciosi M. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med 2009;151(12):854–860.

    Article  PubMed  Google Scholar 

  9. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in patients treated with metformin and sulfonylureas. Diabetologia 2006;49:930–936.

    Article  PubMed  CAS  Google Scholar 

  10. Johnson J, Majumda S, Simpson S, Toth E. Decreased mortality with metformin compared to sulfonylurea monotherapy in type-2 diabetes. Diabetes Care 2002;25(12):2244–2248.

    Article  PubMed  CAS  Google Scholar 

  11. Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high risk patients with type-2 diabetes mellitus. P T 2009;34(9):490–501.

    Google Scholar 

  12. Winkelmayer W, Setoguchi S, Levin R, Solomon D. Comparison of cardiovascular outcomes in elderly patients who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168(21):238–275.

    Article  Google Scholar 

  13. Dormandy JA, Charbonnel B, Eckland DJ. The PROACTIVE Study; pioglitazone in secondary prevention of macrovascular events in patients with type-2 diabetes. Curr Diab Rep 2006;6(1):45–46.

    Article  Google Scholar 

  14. Nissen S, Wolsky K. The effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  15. Singh S, Loke Y, Furberg C. Long term risk of cardiovascular events with rosiglitazone. JAMA 2007;298(10):1189–1195.

    Article  PubMed  CAS  Google Scholar 

  16. Psaty BM, Furberg K. Rosiglitazone and the risk of myocardial infarction (The RECORD trial). N Engl J Med 2007;357:67–69.

    Article  PubMed  CAS  Google Scholar 

  17. Lincoff A, Wolsky K, Nichols S. Pioglitazone and the risk of cardiovascular events in patients with type-2 diabetes. JAMA 2007;298:1180–1188.

    Article  PubMed  CAS  Google Scholar 

  18. Nissen S, Wolsky S, Nichols K, Nesto R. Comparison of pioglitazone and glimepirideon progression of coronary atherosclerosis in patients with type-2 diabetes. The PERISCOPE Trial. JAMA 2008;299(13):1561–1573.

    Article  PubMed  CAS  Google Scholar 

  19. Giugliano D, Esposito K. Pioglitazone vs. glimpeiride and carotid intima media thickness. JAMA 2007;297(12):1315–1316.

    PubMed  CAS  Google Scholar 

  20. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes. Lancet 2003;361:2005–2016.

    Article  PubMed  Google Scholar 

  21. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type-2 diabetes. Lancet 1998;352:837–853.

    Article  Google Scholar 

  22. Malmberg K. The DIGAMI trial. Study of intensive insulin treatment on long term survival after acute myocardial infarction. BMJ 1997;314:1512–1515.

    Article  PubMed  CAS  Google Scholar 

  23. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of the AFCAPS/TexCAPS. JAMA 1998:279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The ALLHAT Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002;288:2998–3007.

    Article  Google Scholar 

  25. Koskinen P, Manttari M, Manninen V. Coronary heart disease incidence in NIDDM patients in Helsinki Heart Study. Diabetes Care 1992;15:820–825.

    Article  PubMed  CAS  Google Scholar 

  26. Shepherd J, Baluw GJ, Murphy MB. Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet 2002;360:1620–1630.

    Article  Google Scholar 

  27. Sever PS, Dahlof B, Poulter NR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the ASCOT-LLA trial. Lancet 2003;361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  28. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type-2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 2004;364:641–642.

    Article  Google Scholar 

  29. Knopp RH, D’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type-2 diabetes. The ASPEN Trial. Diabetes Care 2006;29:1478–1485.

    Article  PubMed  CAS  Google Scholar 

  30. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.

    Google Scholar 

  31. Garber AJ. Attenuating cardiovascular risk factors in patients with type 2 diabetes mellitus. Am Fam Physician 2000;62:2633–2642.

    PubMed  CAS  Google Scholar 

  32. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160–178.

    Article  PubMed  CAS  Google Scholar 

  33. Ginsburg HN, Plutzky J, SobelBE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose lowering. J Cardiovasc Risk 1999;6:337–347.

    Google Scholar 

  34. Tikkanen MJ, Laakso M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. Diabetes Care 1998;21:477–481.

    Article  PubMed  CAS  Google Scholar 

  35. Serruys PW, deFeyterp P, Macaya C (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. The LIPS trial. JAMA 287:3215–3222.

    Article  PubMed  CAS  Google Scholar 

  36. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.

    Article  Google Scholar 

  37. McKenney J. Pharmacologic options for aggressive low density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 2005;96 (suppl):60E–66E.

    Article  PubMed  Google Scholar 

  38. Shepherd J, Blauw GJ, Murphy MB. PROSPER Study Group. Prospective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  39. Knatterud GL, Rosenberg Y, Campeau L. Long term effects on clinical outcome of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation in the post coronary bypass graft trial. Circulation 2000;102:157–165.

    Article  PubMed  CAS  Google Scholar 

  40. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial Investigators. N Engl J Med 1996;335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  41. Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990;6:47.

    Article  PubMed  CAS  Google Scholar 

  42. Robins SJ, Rubins HB, Faas FH. Veterans Affairs HDL intervention Trial. Insulin resistance and cardiovascular events with low HDL cholesterol. The VA-HIT. N Engl J Med 1999;341:410–418.

    Article  PubMed  Google Scholar 

  43. La Rosa JC, Grundy SM, Waters DD. Treating to new targets investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.

    Article  Google Scholar 

  44. Keech A, Simes RJ, Barter P, FIELD Study Investigators. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study). Lancet 2005;366:1849–1861.

    Article  PubMed  CAS  Google Scholar 

  45. McCall KL, Craddock D, Edwards K. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptors blockers on the rate of new onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006;26(9):1297–1306.

    Article  PubMed  CAS  Google Scholar 

  46. Gladstone PSJ, McLaughlin PR, Syvanne M, Steiner G. DAIS Investigators. Micronized fenofibrate decrease progression of coronary heart disease in type-2 diabetes. The DAIS Trial. Circulation 2000;102 (suppl II):II-409.

    Google Scholar 

  47. Canner PL, Berge KG, Wenger NK. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.

    Article  PubMed  CAS  Google Scholar 

  48. Howard B, Roman M, Devereaux R, Fleg J, Galloway J, Henderson J, Howard WJ. Effects of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes; the SANDS Trial. JAMA 2008,299(14):1678–1689.

    Article  PubMed  CAS  Google Scholar 

  49. Blankenhorn DH, Nessin SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.

    Article  PubMed  CAS  Google Scholar 

  50. Rao AK, et al. Platelet coagulation activity in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med 1984;103:82–92.

    PubMed  CAS  Google Scholar 

  51. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type-2 diabetes mellitus. Circulation 2004;110:214–219.

    Article  PubMed  CAS  Google Scholar 

  52. Betteridge DJ. Diabetes, lipoprotein metabolism and atherosclerosis. Br Med Bull 1989;45:285–311.

    PubMed  CAS  Google Scholar 

  53. Imanishi M, Yoshioka K, et al. Glomerular hypertension as one cause of albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int Suppl 1997;63:S198–S200.

    PubMed  CAS  Google Scholar 

  54. The Accord Study Group. Effects of combination lipid therapy in type-2 diabetes mellitus. N Engl J Med 2010;362(17):1563–1574.

    Article  Google Scholar 

  55. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation and atherosclerosis. Am J Cardiol 2002;90 (suppl)27G–33G.

    Article  PubMed  CAS  Google Scholar 

  56. Stergiou GS, Skeva II, et al. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000;35:937–941.

    Article  PubMed  CAS  Google Scholar 

  57. McMurray JJ, Ostergren J, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzymes inhibitors: the CHARM added trial. Lancet 2003;362:767–771.

    Article  PubMed  CAS  Google Scholar 

  58. Arnold JM, Yusuf S, Young J. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107(9):1284–1290.

    Article  PubMed  CAS  Google Scholar 

  59. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, HOPE-TOO Study Investigators. Long term effects of ramipril on cardiovascular events and on diabetes; results of the Hope study extension. Circulation 2005;112(9):1339–1346.

    Article  PubMed  CAS  Google Scholar 

  60. Niskanen L, Hedner T, Hansson L, Lanke J, Nikalson A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first line therapy with an ACE inhibitor compared with a diuretic/beta blocker based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24(12)2091–2096.

    Article  PubMed  CAS  Google Scholar 

  61. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type-2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007;99(7):1006–1012.

    Article  PubMed  CAS  Google Scholar 

  62. Brenner BM, Cooper ME, de Zeeuw D, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001;345(12):861–869.

    Article  PubMed  CAS  Google Scholar 

  63. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy; a randomized double blind crossover trial. Diabetes Care 2003;26(8):2268–2274.

    Article  PubMed  CAS  Google Scholar 

  64. Yusef S, Teo KK, Pogue J, ON TARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–1559.

    Article  Google Scholar 

  65. Mehler PS, Jeffers BW, et al. Associations of hypertension and complications in non-insulin dependent diabetes. Am J Hypertens 1997;10:152–161.

    Article  PubMed  CAS  Google Scholar 

  66. Lindholm LH, Kartman B, Carlberg B, Persson M. Cost implications of development of diabetes in the ALPINE study. J Hypertens Suppl 2006;24(1):S65–S72.

    Article  PubMed  CAS  Google Scholar 

  67. McMurray JJ, Ostergren J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors; The CHARM Added trial. Lancet 2003;362:767–771.

    Article  PubMed  CAS  Google Scholar 

  68. Julius S, Kjeldsen SE, Weber M, VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. The VALUE randomized trial. Lancet 2004;363(4926):2022–2031.

    Article  PubMed  CAS  Google Scholar 

  69. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477–1490.

    Article  Google Scholar 

  70. Yusuf S. Effects of angiotensin receptor blocker telmisartan on cardiovascular events in high risk patients intolerant to angiotensin converting enzyme inhibitors: a randomized controlled trial. Lancet 2008. DOI: 10.1016/S0140-6736(08)61242-8.

  71. Kjeldsen SE, Jamerson KA, Bakris GL. For Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension investigators. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008;17(1):7–17.

    Article  PubMed  CAS  Google Scholar 

  72. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type-2 diabetes with nephropathy. N Engl J Med 2008;35823:2433–2446.

    Article  Google Scholar 

  73. Pfeffer MA, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003;349:1893–1906.

    Article  PubMed  CAS  Google Scholar 

  74. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  75. McKelvie RS, Yusuf S, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction. (RESOLVD) pilot study. Circulation 1999;100:1056–1064.

    Article  PubMed  CAS  Google Scholar 

  76. Rossing P, Parving H, de Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy – fact or fiction? Nephrol Dial Transplant 2006;21(9):2354–2357.

    Article  PubMed  Google Scholar 

  77. The ACCORD Study Group. Effects of Intensive blood pressure control in type-2 diabetes mellitus. N Engl J Med 2010;362(17):1575–1586.

    Article  CAS  Google Scholar 

  78. Pepine C, Handberg E, Cooper-DeHoff R, Marks R. A calcium antagonist versus a non calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INVEST Trial. JAMA 2003;290(21):2805–2816.

    Article  PubMed  CAS  Google Scholar 

  79. Schneider DJ, Sobel BE. Diabetes and Thrombosis. Contemporary Cardiology: Diabetes and Cardiovascular Diseases. Totowa: Humana Press; 2001:149–167.

    Book  Google Scholar 

  80. Aronow H, Califf R, Harrington R, Vallee M, Graffagnino C, Shuaib A. Relation between aspirin dose, all cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol 2008;102:1285–1290.

    Article  PubMed  CAS  Google Scholar 

  81. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension. The HOT trial. Lancet 1998;351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  82. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hcke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625–628.

    Article  PubMed  Google Scholar 

  83. Colwell JA. Position statement: aspirin therapy in diabetes. Diabetes Care 2003;26 (suppl 1):S87–S88.

    PubMed  Google Scholar 

  84. The Post Coronary Artery Bypass Graft Investigators. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336(3):153–163.

    Article  Google Scholar 

  85. Ogawa H, Nakayama M, Morimoto T, Uemora S, Kanauchi M. Low dose aspirin for prevention of primary events in patients with type-2 diabetes: The JPAD trial. JAMA 2008;300(18):2134–2141.

    Article  PubMed  CAS  Google Scholar 

  86. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

    Article  Google Scholar 

  87. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med 2009;150(6):396–404.

    Article  Google Scholar 

  88. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The CHARISMA trial. N Engl J Med 2006;354:1706–1717.

    Article  PubMed  CAS  Google Scholar 

  89. Amarenco P, Donnan G. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke 2004;35:2606–2608.

    Article  PubMed  Google Scholar 

  90. Sacco RL, Diener HC, Yusuf S. Aspirin and extended release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359(12):1238–1251.

    Article  PubMed  CAS  Google Scholar 

  91. Kirtane AJ, Dawkins SG, Colombo A, Grube E, Popna JJ. Paclitaxel eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008;51(7):708–715.

    Article  PubMed  CAS  Google Scholar 

  92. Gress TW, Nieto FJ, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000;342;905–912.

    Article  PubMed  CAS  Google Scholar 

  93. Fogari R, Zoppi A, et al. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatments of non diabetic hypertensive patients. Br J Clin Pharmacol 1998;46;467–471.

    Article  PubMed  CAS  Google Scholar 

  94. Ridker PM, et al. C-reactive protein, the metabolic syndrome, and risk of cardiovascular events: a 8 year follow up of 14,719 initially health American women. Circulation 2003;107:391–397.

    Article  PubMed  Google Scholar 

  95. Vaag AA. Glycemic control and prevention of microvascular and macrovascular events in the Steno 2 study. Endocr Pract 2006;12 (suppl 1):89–92.

    Article  PubMed  Google Scholar 

  96. Rith-Najarian SJ, Reiber GE. Prevention of foot problems in persons with diabetes. J Fam Pract 2000;49:S30–S39.

    PubMed  CAS  Google Scholar 

  97. HOPE Study Investigators. Effects of ramipril in cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the Hope and Micro-Hope Trials. Lancet 2000;355:253–259.

    Article  Google Scholar 

  98. Krentz AJ, Bailey CJ. Oral anti-diabetic agents. Drugs 2005;65(3):385–411.

    Article  PubMed  CAS  Google Scholar 

  99. Nathan DM, Buse MB, Davidson JB. Medical management of hyperglycaemia in type-2 diabetes; a consensus algorithm. Diabetologia 2009;52(1):17–30.

    Article  PubMed  CAS  Google Scholar 

  100. DCCT Research Group. The DCCT trial. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  101. Ohkubo Y. The Kumamoto trial. Diabetes Res Clin Pract 1995;28:103.

    Article  PubMed  CAS  Google Scholar 

Supplementary Readings

  • Agarwal R. Add on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282–2289.

    PubMed  CAS  Google Scholar 

  • Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999;10 (suppl):S30–S39.

    PubMed  CAS  Google Scholar 

  • Azizi M, Linhart A, et al. Pilot study of controlled blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000;18:1839–1147.

    Article  PubMed  CAS  Google Scholar 

  • Chaturvedi N, Sjolle AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28–31.

    Article  PubMed  CAS  Google Scholar 

  • Carvalho CR, et al. Effect of captopril, losartan and bradykinin on early steps of insulin action. Diabetes 1997;46:1950–1957.

    Article  PubMed  CAS  Google Scholar 

  • Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:1011–1030.

    Article  PubMed  CAS  Google Scholar 

  • Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998;19 (suppl):12–16.

    Google Scholar 

  • Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetics: implications of the appropriated blood pressure control in diabetics (ABCD) trial. Am J Cardiol 1998;82:9R–14R.

    Article  PubMed  CAS  Google Scholar 

  • Frick MH, Elo H. Primary prevention trial with gemfiborzil I middle aged men with dyslipidemia. N Engl J Med 1987;317:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  • Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol 1998;81:32B–35B.

    Article  PubMed  CAS  Google Scholar 

  • Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease with type-2 diabetes and nondiabetic subjects with and without previous myocardial infarction: implications for treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N Engl J Med 1998;339:229–234.

    Article  PubMed  CAS  Google Scholar 

  • Hiatt WR. New treatment options in intermittent claudication. Int J Clin Pract Suppl 2001;119:20–27.

    PubMed  CAS  Google Scholar 

  • Jain A, Varma A, Mole R. Digital amputations in the diabetic foot. J Diabetic Foot Complications 2010;2(1)3.

    Google Scholar 

  • Knobl P, Schernthaner G, et al. Hemostatic abnormalities persist despite glycemic improvement by insulin therapy in type 2 diabetics. Thromb Haemost 1994;71:692–697.

    PubMed  CAS  Google Scholar 

  • Kodama M, et al. Antiplatelet drugs attenuate progression of carotid intima thickness in subjects with type 2 diabetes. Thromb Res 2000;97:239–245.

    Article  PubMed  CAS  Google Scholar 

  • McGill JB, et al. Factors responsible for impaired fibrinolysis in obese and diabetic patients. Diabetes 1994;43:104–109.

    Article  PubMed  CAS  Google Scholar 

  • Menys VS, Bhatnagar D, et al. Spontaneous platelet aggregation in whole blood is increased in insulin dependent diabetics. Atherosclerosis 1995;112:115–122.

    Article  PubMed  CAS  Google Scholar 

  • Mogensen CE, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  • New JP, Bilous RW. Insulin sensitivity in hypertensive type 2 diabetic patients after 1 and 19 days with trandolapril. Diabetes Med 2000;17:134–141.

    Article  CAS  Google Scholar 

  • Reid CM, Ryan P, Nelson M. General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol 2001;28:663–667.

    Article  PubMed  CAS  Google Scholar 

  • Rossing K, Christensen PK, et al. Dual blockade of the rennin-angiotensin system in diabetic retinopathy. Diabetes Care 2002;25:95–100.

    Article  PubMed  CAS  Google Scholar 

  • Torlone E, Britta M, Rambotti AM, et al. Improved insulin action and glycemic control after long term angiotensin-converting enzyme induction in subjects with arterial hypertension and type 2 diabetes. Diabetes Care 1993:16:1347–1355.

    Article  PubMed  CAS  Google Scholar 

  • Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J 2000;139:S2–S8.

    Article  PubMed  CAS  Google Scholar 

  • Unger T. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial program. Am J Cardiol 2003;91;28G–34G.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania Health System Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA

    Ronald A. Codario MD, FACP (Clinical Instructor in Medicine)

Authors
  1. Ronald A. Codario MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Diplomate American Board of Internal Medicine

Diplomate American Board of Clinical Lipidology

Diplomate American Board of Vascular Medicine

Clinical Hypertension Specialist (American Society of Hypertension Certified)

Vascular Ultrasound (American Registry of Diagnostic Sonography Certified)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Codario, R.A. (2011). Risk Reduction in the Diabetic Patient. In: Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-441-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-441-8_14

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-440-1

  • Online ISBN: 978-1-60327-441-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation